Literature DB >> 6941374

An international pharmacokinetic study on pirenzepine following a single oral dose.

G Bozler, R Hammer.   

Abstract

Pirenzepine is a very hydrophilic compound. As a consequences its penetration through biomembranes and hence its absorption after oral administration is limited. The variability in plasma pirenzepine after a single oral dose of 50 mg (2 x 25 mg tablet) was investigated in ten countries in a total of 87 volunteers. Pirenzepine was measured by a specific radioimmunoassay. Plasma level profiles were similar in every country with a peak of about 50 ng/ml within two hours after the dose. The mean terminal half-life of disposition was 11 hours. Although the area under the plasma level curve was not normally distributed throughout the population, there was a narrow distribution around the median. It is often accepted that drugs or drug formulations with low bioavailability show high variations in the rates and extent of absorption. Pirenzepine, however, shows consistently uniform plasma level profiles, well within the therapeutic range after multiple dosing (50 mg, twice daily). Only a small proportion of the population may need individual adjustment of the conventional dose regimen.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6941374

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  5 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Absolute bioavailability of pirenzepine in intensive care patients.

Authors:  P Tanswell; F Hofgärtner; G Bozler; H Giesler; G Allmendinger; E Schmid
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Pharmacokinetic and pharmacodynamic studies in man simulating acute and chronic treatment with oral pirenzepine.

Authors:  W Londong; V Londong; C Federle; P Tanswell; U Voderholzer
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Treatment of duodenal ulcer with pirenzepine and cimetidine.

Authors:  H Brunner; H Dittrich; P Kratochvil; G Brandstätter; E Hentschel; K Schütze; K H Tragl; H Kern; K Löffelmann; H Zeiler
Journal:  Gut       Date:  1984-02       Impact factor: 23.059

Review 5.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.